Saskatchewan expands treatment coverage for ALS patients
The province is now offering two new treatments for a fatal neurodegenerative disease under the Saskatchewan Drug Plan.
About 3,000 Canadians live with amyotrophic lateral sclerosis (ALS), a disease that causes patients to rapidly lose the ability to speak and move.
Two more treatments meant to extend an improved quality of life for eligible patients are now covered under the Government of Saskatchewan’s publicly funded drug plan.
As of Friday, eligible ALS patients meeting certain medical criteria can be considered for coverage of Albrozia and the oral suspension of Radicava under the Saskatchewan Drug Plan.